1. Home
  2. FBYD vs SABS Comparison

FBYD vs SABS Comparison

Compare FBYD & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Falcon's Beyond Global Inc.

FBYD

Falcon's Beyond Global Inc.

HOLD

Current Price

$11.28

Market Cap

204.8M

Sector

N/A

ML Signal

HOLD

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

HOLD

Current Price

$3.88

Market Cap

201.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FBYD
SABS
Founded
2021
2014
Country
United States
United States
Employees
207
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
204.8M
201.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
FBYD
SABS
Price
$11.28
$3.88
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$9.80
AVG Volume (30 Days)
108.9K
779.9K
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$268.88
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.71
$1.00
52 Week High
$29.02
$6.60

Technical Indicators

Market Signals
Indicator
FBYD
SABS
Relative Strength Index (RSI) 61.15 47.53
Support Level $10.27 $3.69
Resistance Level $13.05 $4.16
Average True Range (ATR) 1.81 0.19
MACD 0.57 -0.01
Stochastic Oscillator 53.39 25.78

Price Performance

Historical Comparison
FBYD
SABS

About FBYD Falcon's Beyond Global Inc.

Falcons Beyond Global Inc. is a Company that provides a full range of theme park design, master planning, and experiential technologies for customers in the entertainment and attraction industry through its Falcon's Creative Group reportable segment and develops and co-owns resort and theme park attractions through its Destinations Operations. The Company has four operating segments, Falcon's Creative Group, PDP, Falcon's Beyond Brands, and Destinations Operations, all of which are reportable segments. It earns the majority of the revenue from Falcon's Creative Group segment.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Share on Social Networks: